Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis

被引：10

作者：

Xavier, Camila Braganca ^{[1
]}

Holanda Lopes, Carlos Diego ^{[1
]}

Harada, Guilherme ^{[1
]}

Bariani Peres, Eduardo Dante ^{[2
]}

Katz, Artur ^{[1
]}

Jardim, Denis Leonardo ^{[1
]}

机构：

[1] Hosp Sirio Libanes, Oncol Ctr, Sao Paulo, Brazil

[2] Hosp Sirio Libanes, Cardiol Ctr, Sao Paulo, Brazil

来源：

TRANSLATIONAL ONCOLOGY | 2022年 / 19卷

关键词：

Cardiovascular toxicity; Checkpoint blockade; Immune checkpoint inhibitors; Meta-analysis; abbreviations; AES; Adverse effects; BSC; Best supportive care; CTCAE; Common toxicity criteria; CTLA-4; Cytotoxic t-lymphocyte-associated antigen 4; CV; Cardiovascular; FAERS; US food and drug administration adverse; events reporting system; ICIS; PRISMA; Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCTs; randomized clinical trials; PD-1; programmed cell death protein 1; PD-L1; programmed cell death ligand 1; RR; relative risk; ADVANCED HEPATOCELLULAR-CARCINOMA; SQUAMOUS-CELL CARCINOMA; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; 2ND-LINE THERAPY; NIVOLUMAB NIVO; CHEMOTHERAPY; CANCER; PEMBROLIZUMAB;

D O I：

10.1016/j.tranon.2022.101383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Immune checkpoint inhibitors may be associated with multiple immune-related toxicities. Cardiovascular adverse effects are underreported in clinical trials. Methods: We conducted a systematic review and meta-analysis to evaluate cardiovascular adverse effects incidence among patients with solid tumors receiving immune checkpoint inhibitors in randomized clinical trials and the relative risk of presenting these effects compared to placebo or best supportive care. The search was conducted through MEDLINE, Embase, and Scopus databases from January 1st, 2010 until July 1st, 2020. Outcomes were reported following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Results: 57 randomized clinical trials including 12,118 patients were included. All grade CV AEs incidence rate was 8.32% (95% CI = 6.35%-10.53%). When only grade 3-5 CV AEs were considered, ICIs were significantly associated with increased risk than placebo or BSC (RR = 1.36; 95% CI = 1.06-1.73; p = 0.01). Conclusion: This meta-analysis corroborates the hypothesis of increased CV risk related to immune checkpoint inhibitors.

引用

页数：10

共 81 条

[1] Recurrent Myocarditis Induced by Immune-Checkpoint inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment [J].

Aghel, Nazanin ;

Gustafson, Dakota ;

Di Meo, Ashley ;

Music, Milena ;

Prassas, Ioannis ;

Seidman, Michael A. ;

Hansen, Aaron R. ;

Thavendiranathan, Paaladinesh ;

Diamandis, Eleftherios P. ;

Delgado, Diego ;

Fish, Jason E. .

JCO PRECISION ONCOLOGY, 2021, 5 :485-491

[2] Original Research Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials [J].

Agostinetto, Elisa ;

Eiger, Daniel ;

Lambertini, Matteo ;

Ceppi, Marcello ;

Bruzzone, Marco ;

Ponde, Noam ;

Plummer, Chris ;

Awada, Ahmad H. ;

Santoro, Armando ;

Piccart-Gebhart, Martine ;

de Azambuja, Evandro .

EUROPEAN JOURNAL OF CANCER, 2021, 148 :76-91

[3]

[Anonymous], CTCAE V4 03

[4]

[Anonymous], FDA ADVERSE EVENT RE

[5]

[Anonymous], 2020, Review Manager (RevMan) Computer program. Version 5.4

[6] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[7]

Arance H.Gogas, ANN ONCOL

[8] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[9]

Balar A.V., 2018, JCO, V36

[10]

Bang Y.-.J., 2016, JCO, V34, pTPS4135

← 1 2 3 4 5 6 7 8 9 →